Effect of Montelukast on Basophils, In-vitro
This trial is active, not recruiting.
|Conditions||allergic asthma, allergic rhinitis|
|Collaborator||Merck Sharp & Dohme Corp.|
|Start date||May 2008|
|End date||September 2011|
|Trial size||15 participants|
|Trial identifier||NCT00710450, Townley Merck|
Subjects with either allergic asthma or allergic rhinitis will be recruited to obtain blood. This blood will be used to be stimulated with to whatever the patient allergic. In the laboratory, this stimulated blood will be measured for histamine, leukotrienes, IL-13 and IL-3. These are chemicals responsible for allergy symptoms.
time frame: during the assay portion.
Cytokine release. IL-13, IL-4 and leukotriene
time frame: assay portion
Male or female participants at least 12 years old.
Inclusion Criteria: - Allergic asthma or allergic rhinitis - age 12+ Exclusion Criteria: - smokers
|Official title||The Effect of Montelukast In-vitro on Basophil Histamine and Leukotriene, IL-4 Adn IL-13 Release in Subjects With Allergic Rhinitis or Allergic Asthma|
Call for more information